Literature DB >> 30205322

Isofraxidin inhibits interleukin-1β induced inflammatory response in human osteoarthritis chondrocytes.

Jian Lin1, Xiaobin Li1, Weihui Qi1, Yingzhao Yan1, Kai Chen1, Xinghe Xue1, Xinxian Xu1, Zhenhua Feng1, Xiaoyun Pan2.   

Abstract

Osteoarthritis (OA) is the most prevalent disease of knee especially in the aged people. Isofraxidin (IF) is a coumarin compound refined from traditional Chinese medicines with potential anti-inflammatory ability. This study aimed to evaluate protective anti-inflammatory effects of IF in human OA chondrocytes. The chondrocytes were isolated from OA patients and pretreated with IF before treatment with IL-1β. The results showed that IF blocked IL-1β-stimulated production of NO and PGE2. In addition, IF inhibited the expression of COX-2, iNOs, MMP-1, MMP-3, MMP-13, ADAMTS-4 and ADAMTS-5, and increased the levels of aggrecan and collagen-II. Mechanistically, IF suppressed IL-1β-induced IκB-α degradation and NF-κB activation. In conclusion, our results demonstrate that IF inhibits inflammation in OA via the regulation of NF-κB signaling, and suggest that IF may be a potential therapeutic agent for OA.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chondrocytes; Inflammation; Isofraxidin; NF-κB; Osteoarthritis

Mesh:

Substances:

Year:  2018        PMID: 30205322     DOI: 10.1016/j.intimp.2018.09.003

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  7 in total

1.  Isofraxidin Alleviates Myocardial Infarction Through NLRP3 Inflammasome Inhibition.

Authors:  Guofan Chen; Xiaozheng Song; Dongming Lin; Peng Xu
Journal:  Inflammation       Date:  2020-04       Impact factor: 4.092

Review 2.  Small molecules of herbal origin for osteoarthritis treatment: in vitro and in vivo evidence.

Authors:  Penghui Zhang; Kaihu Li; Amir Kamali; Reihane Ziadlou; Paras Ahmad; Xinluan Wang; R Geoff Richards; Mauro Alini; Valentina Basoli; Zhen Li; Sibylle Grad
Journal:  Arthritis Res Ther       Date:  2022-05-11       Impact factor: 5.606

Review 3.  Isofraxidin: Synthesis, Biosynthesis, Isolation, Pharmacokinetic and Pharmacological Properties.

Authors:  Mohammad Bagher Majnooni; Sajad Fakhri; Yalda Shokoohinia; Mahdi Mojarrab; Sara Kazemi-Afrakoti; Mohammad Hosein Farzaei
Journal:  Molecules       Date:  2020-04-27       Impact factor: 4.411

4.  Isofraxidin Inhibits Receptor Activator of Nuclear Factor-κB Ligand-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages Isolated from Sprague-Dawley Rats by Regulating NF-κB/NFATc1 and Akt/NFATc1 Signaling Pathways.

Authors:  Wei Wang; Bo Wang
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

5.  Inhibiting TLR4 signaling by linarin for preventing inflammatory response in osteoarthritis.

Authors:  Weihui Qi; Yanlin Chen; Shuaibo Sun; Xinxian Xu; Jingdi Zhan; Zijian Yan; Ping Shang; Xiaoyun Pan; Haixiao Liu
Journal:  Aging (Albany NY)       Date:  2021-02-01       Impact factor: 5.682

Review 6.  Targeting Oxidative Stress and Inflammation in Intervertebral Disc Degeneration: Therapeutic Perspectives of Phytochemicals.

Authors:  Liang Kang; Huaqing Zhang; Chongyu Jia; Renjie Zhang; Cailiang Shen
Journal:  Front Pharmacol       Date:  2022-07-12       Impact factor: 5.988

Review 7.  A review on the immunomodulatory activity of Acanthopanax senticosus and its active components.

Authors:  Kit-Man Lau; Grace Gar-Lee Yue; Yuk-Yu Chan; Hin-Fai Kwok; Si Gao; Chun-Wai Wong; Clara Bik-San Lau
Journal:  Chin Med       Date:  2019-07-31       Impact factor: 5.455

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.